Effect of Glucagon-like Peptide 1 (GLP-1) on Microvascular Myocardial Function in Patients With Type 2 Diabetes.
PHASE4CompletedINTERVENTIONAL
Enrollment
20
Participants
Timeline
Start Date
May 31, 2013
Primary Completion Date
April 30, 2014
Study Completion Date
April 30, 2014
Conditions
Type 2 DiabetesMicrovascular Dysfunction
Interventions
DRUG
Victoza
Trial Locations (1)
2400
Bispebjerg Hospital, Copenhagen
All Listed Sponsors
lead
Bispebjerg Hospital
OTHER
NCT01931982 - Effect of Glucagon-like Peptide 1 (GLP-1) on Microvascular Myocardial Function in Patients With Type 2 Diabetes. | Biotech Hunter | Biotech Hunter